Royalties from Licenses

Go to the previous topic

RF Financial Concepts 101 

Understanding the Business of the RF

Module 1: Understanding RF Sources of Income 

Funds Generated From Intellectual Property (IP) Commercialization

The RF provides innovation support services to the SUNY research community. These services help move technology and invention to the marketplace for public benefit.

Executing a license for a new technology or discovery is a key milestone in the intellectual property commercialization process and eventually yields one of the four primary sources of RF funds - royalty income.

What the Data Shows
Royalties from licenses is a source of RF funds, representing 1% of the total projected amount for 2018, for a total of $9.8 million.


Where to Find More Information 

Please refer to the 2018 Operating Plan.  

Licensing of Inventions Drives Royalty Income

Xiaflex innovation medical

An example of an invention that yields royalty income is XIAFLEX®, the first non-surgical treatment of Dupuytren’s disease developed by researchers at Stony Brook University.

Following FDA approval in 2010, the drug has been administered to more than 40,000 patients in the United States and 46 Eurasian countries. It is approved in Canada and under review or to be submitted for review in other countries such as Japan, Australia, Mexico and Brazil.

In addition to Dupuytren's disease, XIAFLEX® is under clinical investigation by Endo Pharmaceuticals for new potential indications developed by researchers at Stony Brook University including adhesive capsulitis and cellulite. Highly statistically significant data from Endo's Phase 2b study of XIAFLEX® in patients with cellulite were presented at the Aesthetica Super Symposium (American Society of Plastic Surgeons) in March 2017 and the American Academy of Dermatology Annual Meeting in February 2017. Endo plans to initiate Phase 3 clinical trials of XIAFLEX for the treatment of cellulite in the second half of 2017.

Go to the next topic